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Abstract  The  histological  type  of  tumour  according  to  the  WHO:  ductal,  lobular,  rare  forms,
is correlated  with  speciﬁc  aspects  of  the  imaging  based  on  each  type.  This  morphological  clas-
siﬁcation  was  improved  by  knowledge  of  the  molecular  anomalies  of  breast  cancers,  resulting
in the  deﬁnition  of  cancer  sub-groups  with  distinct  prognoses  and  different  responses  to  treat-
ment: luminal  A,  luminal  B,  HER2  positive,  basal-like,  triple-negative.  Studies  are  beginning  toMolecular
classiﬁcation
deal with  the  appearance  of  each  sub-type  in  the  imaging.  It  is  now  important  for  the  radiologist
to be  familiar  with  them.
© 2013  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
According  to  the  WHO,  the  type  and  histological  grade  of  the  tumour  are  indispens-
able  diagnostic  and  prognostic  morphological  elements  for  the  care  of  breast  cancer.
The  prognostic  and  predictive  elements  of  the  response  to  treatment  are  also  impor-
tant,  that  is,  in  addition  to  the  histological  grade,  the  hormone  receptors  (oestrogen
receptors  [OR]  and  progesterone  [PR]  receptors)  and  the  HER2  status.  New  techniques  of
molecular  biology  (‘‘arrays’’)  now  allow  for  simultaneous  analysis,  for  a  single  tumour,
of  the  ampliﬁcation  status  or  deletion  of  thousands  of  DNA  sequences  as  well  as  the
level  of  expression  of  RNAm  of  thousands  of  genes  to  determine  discriminating  proﬁles
of  chromosome  alteration  or  gene  expression.  The  breast  cancers,  in  particular  the  inﬁl-
trating  ductal  carcinomas,  are  thereby  reclassiﬁed  according  to  the  genome  alterations
underlying  very  different  prognoses:  this  is  the  molecular  or  ‘‘intrinsic’’  classiﬁcation  dis-
tinguishing  the  luminal  A,  luminal  B,  HER2  positive,  basal-like,  triple-negative  sub-types.
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enome  tests  determining  a  prognostic  signature  have
eveloped  although  they  do  not  currently  have  any  clinical
pplication  in  France.  However,  correlations  between  this
olecular  data  and  the  morphology,  the  immunohistochem-
cal  grade  and  proﬁle  of  inﬁltrating  carcinomas  have  been
stablished.
We  propose  reviewing  the  ‘‘classic’’  radio-histological
spects  of  inﬁltrating  carcinomas  according  to  their  mor-
hology  and  then  the  imaging  aspects  according  to
‘traditional’’  histoprognostic  factors  and  then  describe  the
ew  molecular  classiﬁcation  that  the  radiologist  should  now
e  familiar  with.  Although  there  has  recently  been  a  fairly
bundant  literature  in  molecular  biology  and  clinical  oncol-
gy  on  breast  cancers,  the  same  is  not  true  about  the
orrelations  between  tumour  sub-type  and  imaging.  Studies
n  the  literature  concerning  aspects  of  the  mammography,
onography  and  MRI  are  still  numerous,  retrospective  and
ith  different  methodologies.
orrelations between imaging and WHO
istological types (XXth century)nitially,  the  WHO  deﬁned  breast  cancer  by  its  morphological
nd  immunohistochemical  characteristics  [1].
igure 1. Inﬁltrating ductal carcinoma. a: core biopsy under sonograp
nﬁltrating proliferation; b: HES × 64. Formation of tubes and framework
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nﬁltrating ductal carcinoma (IDC)
t  accounts  for  70  to  80%  of  the  inﬁltrating  cancers.  Macro-
copically,  it  involves  a  hard  tumour  with  star-shaped
utlines,  rarely  of  soft  consistency  or  with  sharp  outlines.
he  histoprognostic  grading  takes  into  account  the  differ-
ntiation  (formation  of  tubes  or  glandular  tissue),  nuclear
typies  and  mitoses  (counted  in  the  most  active  zone),
etermining  three  grades  of  malignancy  (Figs.  1a,  b).
The  aspects  in  the  imaging  are  known:  irregular  or  stellar
ass  (Fig.  1c),  architectural  distortion,  microcalciﬁcations,
arely  round  mass.
nﬁltrating lobular carcinoma (ILC)
t  accounts  for  5 to  15%  of  the  inﬁltrating  cancers.  Macro-
copically  it  consists  of  a  lesion  that  is  more  palpable  than
isible.  The  tumoral  inﬁltration  often  complies  with  the
re-existing  architecture  of  the  breast  tissue.  The  loss  of
xpression  of  l’E-cadherine,  an  intercellular  adhesion  pro-
ein  (diagnosed  in  immunohistochemistry  by  the  absence  of
embrane  marking),  deﬁnes  ILC  whose  cells  are  no  longerhy: destruction of the normal epithelial structures by a malignant
; c: sonogram: irregular mass of 5 mm.
ohesive.  The  cells  are  small,  isolated  or  in  ‘‘Indian  ﬁle’’,
urrounding  canals  or  inﬁltrating  the  links  of  the  fat  tissue
ithout  reaction  stroma  (Figs.  2a,  b).  This  partly  accounts
or  the  difﬁculties  in  detecting  it.
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Figure 2. Inﬁltrating lobular carcinoma. a: microbiopsy under sonography: inﬁltration of the fat tissue by isolated cells without ﬁbrous
’; c: 
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[stroma reaction; b: HES × 160. Arrangement of cells in ‘‘Indian ﬁle’
of the upper quadrants, recently appeared.
The  radio-clinical  discordance  is  evocative,  between  a
diffuse  cutaneous  condition  without  individualised  nodule
and  a  slight  translation  in  mammography:  isolated  distor-
tion  of  the  architecture  (microcalciﬁcations  are  rare),  focal
asymmetry  of  density  (Fig.  2c),  anomaly  often  detected  on
one  incidence  (cranio-caudal  view).  The  progressive  reduc-
tion  in  the  size  of  the  breast  is  rare  but  evocative  with
an  extensive  mass,  accounting  for  the  lack  of  spread  of
the  gland  under  compression.  Harvey  compared  the  tumoral
inﬁltration  with  a  ‘‘spider’s  web’’  [2].  The  MRI  is  the  best
examination  for  the  detection  and  measurement  of  the  size
of  ILC  [3].
Mucinous carcinoma
The  term  is  reserved  for  the  pure  form  (with  a  very  good
prognosis)  of  this  carcinoma  that  accounts  for  2%  of  all
inﬁltrating  carcinomas.  It  consists  of  large  patches  of  extra-
cellular  mucus  within  which  ﬂoat  islands  of  malignant  cells
(Fig.  3a).
T
I
imammogram, right oblique image: focal hyperdensity at the union
Classically,  it  appears  in  the  imaging  as  a  round  mass,
ith  a rather  circumscribed  edge  that,  in  the  sonogram,  may
e  mistaken  for  a  cyst  with  thick  contents  [4]  (Figs.  3b,  c).
n  the  MRI,  a  hyperdense  signal  in  T2  due  to  the  mucinous
ontent  of  the  walls  that  are  enhanced  is  indicative  [5].
edullary carcinoma
ccounting  for  2%  of  all  inﬁltrating  carcinomas,  often
elated  to  a  BRAC1  mutation,  this  is  a  carcinoma  with  dis-
inct  outlines  consisting  of  little  differentiated  cells  with  a
oderate  to  marked  lymphoid  inﬁltrate  and  little  abundant
troma  (Fig.  4).  In  the  mammogram,  it  consists  of  a  very
ense  round  mass  with  a  circumscribed  or  indistinct  edge
2].ubular carcinoma
nitially  rare  (1%  of  the  inﬁltrating  carcinomas),  it  is  becom-
ng  more  common  with  the  generalisation  of  screening.  It  is  a
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Figure 3. Mucinous cancer. a: HES × 25. Cluster of tumoral cells ﬂoatin
with a slightly microlobulated edge; c: sonogram: mass parallel with mic
Figure 4. Medullary cancer. HES × 25. Appearance of poorly dif-
ferentiated grade III inﬁltrating ductal carcinoma with very high
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a  stroma  reaction  and  have  a  round  shape.  Shin  et  al.  [8]
has  shown  that  the  very  dense  masses  with  a  circumscribedymphoid inﬁltrate (arrow).
ard,  star-shaped  lesion  formed  by  regular  cells  deposited  in
ubules,  surrounded  by  an  abundant  ﬁbrous  stroma  (Fig.  5a).
The  imaging  is  typically  a  stellar  mass  with  a  very  small
ense  centre  or  an  architectural  distortion  (Fig.  5b),  more
arely  a  round  mass  or  amorphous  microcalcifcations  [6].
o
ag in pools of mucus; b: mammogram, spot compression: oval mass
rolobulated edge, isoechogenic with posterior enhancement.
There  are  other,  rare  morphological  types:  the  WHO  clas-
iﬁcation  has  established  21  of  them,  some  not  exceeding  a
ozen  cases  described  in  the  literature.
orrelations between the imaging and
‘traditional’’ prognostic and predictive
actors (beginning 2000)
t  the  beginning  of  the  2000s,  several  authors  demonstrated
hat  factors  such  as  the  tumour  grade  and  the  hormone
eceptors  (oestrogens,  progesterone)  have  an  inﬂuence  on
he  appearance  of  the  imaging  [7,8].
he grade
airly  slow  developing  grade  I tumours  (low  grade)  and  grade
I  tumours  (intermediate  grade)  present  a  stroma  reaction
esulting  in  imaging  by  spicules  and  a  peri-lesional  hyper-
chogenic  halo  (Fig.  6a).  Grade  III  (high  grade)  is  the  most
ggressive  and  these  tumours  respond  well  to  chemotherapy.
f  rapid  evolution,  these  grade  III  cancers  do  not  developr  microlobulated  outline,  with  posterior  reinforcement  are
ssociated  with  a  high  grade  and  negativity  of  hormone
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Figure 5. Tubular carcinoma. a: macroscopy: star-shaped, spiculated lesion and inﬁltration of the peripheral fat; b: mammogram:
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marchitectural distortion at the union of the upper quadrants (arrow
receptors.  Vascularisation  by  colour  doppler  is  generally
associated  with  a  high  grade  [8]  (Fig.  6b).
Hormone receptors
The  immunohistochemical  detection  of  receptors  uses
unmasking  methods  of  antigen  sites  by  sensitive  antibod-
ies  (Fig.  7a).  These  receptors  are  detected  in  the  nuclei  of
inﬁltrating  tumour  cells  and  the  neighbouring  breast  tissue
is  used  as  an  internal  control.  The  threshold  of  positivity  is
generally  10%  of  the  marked  cells  [9].  The  presence  of  these
receptors  (RH  +  tumour)  is  a  good  prognosis  and  indicates  a
hormone-sensitive  tumour.  Their  absence  is  a  less  favourable
prognosis.  R−  tumours  respond  better  to  chemotherapy.
In  the  imaging,  R+  cancers  often  have  an  irregular
shape  (80%)  and  spiculated  outlines  (68%),  signiﬁcantly
more  frequent  than  triple-negative  cancers  [10]  (Fig.  7b).
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Figure 6. Sonography aspects as a function of the tumour grade. a
centimetric hypoechogenic centre surrounded by a very hard echogenic ha
grade III. Sonogram: very hypoechogenic, oval mass with a circumscribed peripheral  echogenic  halo  is  noted  in  64%  of  all  R+HER−
ancers  [11].
Chen  et  al.  compared  the  MRI  appearance  of  R+  and  R−
ancers.  The  most  frequent  mode  of  presentation  was  the
ass  in  both  groups.  No  R+  cancer  was  presented  with  a  non-
ass,  observed  in  18%  of  R−  tumours.  The  MRI  presentation
f  R−  cancers  attests  to  their  aggressiveness:  signiﬁcantly
ore  frequent  enhancement  with  wash-out,  greater  size  and
denopathies  [12].
Teifke  et  al.  studied  the  correlations  between  the  fac-
ors  of  histopathological  prognosis  comprising  the  grade  and
ormone  status  and  the  annular  enhancement  in  MRI  [13].
here  was  a  signiﬁcant  increase  in  the  peripheral-central-
icrovessel  ratio  in  grade  3,  R−  and  N+  tumours,  accountingor  the  annular  enhancement.  According  to  Teifke,  this  is
he  most  precise  MRI  criterion  to  predict  the  negativity  of
ormone  receptors,  high  grade  and  ganglion  invasion  [13]
Fig.  7c).
: inﬁltrating ductal carcinoma grade I. Sonogram: masse with a
lo in elastography (200 Kpa), ACR5; b: inﬁltrating ductal carcinoma
 edge, with posterior enhancement, vascularized, ACR 4.
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Figure 7. Aspects according to the hormone status. a: immunohistochemistry: inﬁltrating ductal carcinoma with strong expression of the
estrogen receptor in the nuclei of 100% of the tumour cells; b: ﬁfty-ﬁve years, inﬁltrating ductal carcinoma grade I, oestrogen receptors = 90%.
Sonogram: hypoechogenic, irregular mass with angular edges; c: forty-three years, left inﬁltrating ductal carcinoma grade 3, R−, HER2−,
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r+. MRI after injection: round mass with annular enhancement.
ER2 status
ER2  (or  c-erbB2)  is  a  proto-oncogene  located  on  chromo-
ome  17.  The  ampliﬁcation  or  over-expression  is  observed
n  10  to  30%  of  all  cancers.  The  HER2  status  was  a
actor  of  a  poor  prognosis  before  the  introduction  of  treat-
ent  with  trastuzumab  and  is  a  predictive  factor  of  a
esponse  to  anti-HER2  therapies.  This  sub-type  of  cancer
eneﬁts  from  ‘‘targeted’’  therapies,  treatments  directed
gainst  the  relatively  speciﬁc  molecular  anomalies  of  cancer
ells,  here  molecules  targeting  the  family  of  HER2  recep-
ors.
The  immunohistochemistry  assesses  the  intensity  of  the
arking  and  the  percentage  of  cells  presenting  a  circumfer-
ntial  membrane  marking  attesting  to  the  over-expression
f  the  HER2  membrane  protein  (Fig.  8a).  When  the  result
s  equivocal  (score  2  +),  a  complementary  study  by  FISH  is
equested  (in  situ  ﬂuorescent  hybridisation  that  detects  the
mpliﬁcation  of  the  gene)  (Fig.  8b).
With  the  development  of  the  new  molecular  classiﬁ-
ation,  studies  have  been  carried  out  on  the  correlations
etween  imaging  and  HER2  status.
he new molecular classiﬁcation (XXIst
entury)
t  was  ﬁrst  described  by  Perou  in  Nature  in  2000,  turn-
ng  an  analytical  tool  based  on  the  morphological  type  of
i
t
a
sancer  into  an  analytical  tool  based  on  the  analysis  of  over
0,000  genes.  The  main  molecular  types  of  inﬁltrating  car-
inomas  are  described  on  the  basis  of  differently  expressed
enes  according  to  the  tumoral  type  or  ‘‘intrinsic  signature’’
14].
uminal A type
t  expresses  cell  proteins  located  towards  the  lumen  of  the
ucts,  thereby  called  ‘‘luminal’’.  It  accounts  for  50  to  60%
f  all  breast  cancers.  It  is  characterized  by  a  high  expression
f  genes  of  oestrogen  receptors  (OR),  a  high  expression  of
enes  regulated  by  OR  (GATA-3,  FOX  A1,  etc.),  a low  expres-
ion  of  genes  related  to  the  proliferation  and  an  absence
f  over-expression  of  HER2.  P53  is  mutated  in  13%  of  the
ases.
As  regards  the  phenotype,  in  clinical  practice,  this  type
orresponds  to  tubular  carcinoma  and  grade  I  or  II IDC  or  ILC,
xpressing  oestrogen  receptors  (R+),  with  a  low  index  of  pro-
iferation  (Ki67  <  14%,  interpreted  in  immunohistochemistry
echnique).
In  the  mammogram,  in  the  Taneja  study,  the  spiculated
ass  is  signiﬁcantly  more  common  in  the  luminal  groups
37%)  than  in  the  other  sub-types  [15]  (Fig.  9).  By  sonog-
aphy,  all  the  criteria  of  malignancy  are  often  observed:
rregular  shape,  angular  or  spiculated,  echogenic  halo,  pos-
erior  attenuation  [16]. The  tumour-parenchyma  interface
ttests  to  the  desmoplastic  reaction  and  therefore  a  fairly
low  growth.
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Figure 8. HER2 status. a: immunohistochemistry: circumferential and intense membrane marking attesting to the over-expression of the
HER2 membrane protein (Score 3+). Absence of marking of the benign mammary ducts (internal control of speciﬁcity). b: FISH (in situ
ﬂuorescent hybridization) of the same case showing ampliﬁcation of gene HER2 represented by two red spots. Formation of clusters of over
10 spots (copies of HER2) by tumor cell nuclei.
Figure 9. Luminal A sub-type. a: mammogram: spiculated (palpable) mass of 50 mm. Inﬁltrating ductal carcinoma grade I, oestrogen
receptors/progesterone receptors = 90%, Ki67 < 14%, HER2−. b: same patient. MRI after injection: irregular spiculated mass. c: same patient.
rapy:
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tMammography control after 4 months of neo-adjuvant hormone the
Luminal B type
It  accounts  for  about  20%  of  all  breast  cancers.  Compared
with  the  luminal  A  group,  it  comprises  a  lower  expres-
sion  of  OR  genes,  a  lower  expression  of  OR-regulated
genes  (GATA-3,  FOX  A1,  etc.),  and  a  high  expression  of
proliferation-related  genes.  P53  is  mutated  in  66%  of  the
cases.As  regards  the  phenotype,  in  clinical  practice,  this  type
corresponds  to  grade  II  or  III  inﬁltrating  carcinomas,  express-
ing  oestrogen  receptors  (R+),  with  Her2  Score  0,  1+,  2+
not  ampliﬁed,  with  a  high  proliferation  index  (KI67  >  14%)
w
r
f
t reduction in the size of the mass.
Fig.  10a).  Carcinomas  occurring  with  BRCA  2  mutations
ften  belong  to  this  molecular  type.
As  noted  in  the  Taneja  study,  the  spiculated  mass  was
ore  often  signiﬁcantly  observed  in  luminal  groups  when
ompared  with  other  sub-types.  They  occur  less  often  in  the
uminal  B  type  (27%)  than  in  the  luminal  A  type  (37%).  Archi-
ectural  distortion  was  more  often  observed  in  the  luminal  B
ype  (16%)  than  in  the  other  sub-types  [15]. However,  there
ere  only  44  cases  of  luminal  B  type  in  this  study.  By  sonog-
aphy,  Au-Yong  observed  a  statistically  signiﬁcant  irregular
orm  (88%  of  the  cases)  and  posterior  attenuation  (85%  of
he  cases)  [16].  However,  the  examination  was  carried  out
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Figure 10. Luminal B sub-type. a: immunohistochemistry: ER = 90%, progesterone receptors = 20%, no over-expression of HER2, Ki67 > 14%.
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t: sonogram: mass with indistinct edges, moderately hypoechogeni
oma grade II, oestrogen receptors = 70% PR = 20%, HER2−, KI67 = 16
ith  a  7.5  mHz  probe  and  the  authors  acknowledge  that  they
ould  certainly  have  obtained  different  results  with  more
ecent  equipment  (Fig.  10b).
ER2 type
t  accounts  for  10%  of  all  breast  cancers.  It  is  characterized
y  the  absence  of  OR-related  genes,  the  high  expression
f  genes  on  the  HER2  amplicon  (GRB7, etc.)  and  the  high
xpression  of  proliferation-related  genes.  P53  is  mutated  in
1%  of  the  cases.
As  regards  the  phenotype,  in  clinical  practice,  this  type
orresponds  to  grade  II  or  II  inﬁltrating  carcinomas,  not
xpressing  oestrogen  (R−)  receptors,  with  Her2  Score  3+  or
+  in  FISH  ampliﬁed  immunohistochemistry,  whatever  the
I67.
In  the  imaging,  a  mass  with  indistinct  outlines  is  the
ost  common  mode  of  presentation:  42%  in  the  Taneja
t  al.  series  [15].  A  mass  with  indistinct  outlines  is  sig-
iﬁcantly  associated  with  a  high  grade,  a  R−  status  and
ER2+  [8].  The  presence  of  calciﬁcations  in  the  mammogram
F
g
h
[th a high peri-lesional elastography score. Inﬁltrating ductal carci-
onservative treatment, adjuvant chemotherapy, hormone therapy.
polymorphous,  in  the  mass  or  in  segmental  distribution  clus-
er)  is  signiﬁcantly  associated  with  a HER2  +  status:  their
resence  may  predict  a  HER2+  status  when  the  HER2  score
s  equivocally  2+  in  the  microbiopsy  (in  immunohistochem-
stry)  [8]. In  sonography,  a  rather  irregular  mass  is  observed
hose  edges  are  described  in  different  ways  in  the  liter-
ture.  However,  the  assessment  of  the  outlines  depends
n  the  apparatus  and  the  reading  by  the  operator:  signif-
cantly  indistinct  edges  in  94%  of  the  masses  for  Au-Yong
t  al.  [16],  but  spiculated  edges  in  56%  of  the  cases  by
ang  et  al.  [17]. This  author  concludes  that  the  spicu-
ated  edges  help  predict  the  HER2+  status  more  than  the
egative  receptors  [17].  When  at  the  tumour-parenchyma
nterface,  it  is  more  often  abrupt  in  R-HER2+  tumours  (91%)
han  in  R+HER2−  cancers  (64%)  [11].  The  posterior  enhance-
ent  is  more  often  observed  in  R−HER2+  cancers  (50%)
han  in  R+HER2−  cancers  (29%)  in  the  Ko  et  al.  study  [11].
inally,  non-masses  are  most  often  observed  in  the  HER2+
roup:  32%  as  opposed  to  16%  of  the  RE+RP−HER2−, per-
aps  because  the  intraductal  component  is  more  frequent
8]  (Fig.  11).
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Figure 11. HER2 + sub-types. a: thirty-three years, palpable mass of 6 cm. Mammogram: non-sillhouetted mass, presence of several
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apolymorphous microcalciﬁcations. Inﬁltrating ductal carcinoma grad
seven years. Sonogram: 15 mm mass with an abrupt interface. Inﬁl
chemotherapy and Trastuzumab. c:thirty-six years. Sonogram: ‘‘non
Basal-like type
It  accounts  for  10%  of  all  breast  cancers  and  56  to  85%  of
the  triple-negative  (TN)  cancers  [18,19].  It  expresses  the
cytokeratins  (CK)  of  high  molecular  weight  (ﬁbrous  intra-
cellular  polypeptides)  or  basal  CK  (named  so  because  of
their  expression  in  the  basal  or  myoepithelial  cells  of  the
normal  milk  ducts).  It  is  characterised  by  the  absence  of
OR  expression,  the  expression  of  high  molecular  weight
keratin  genes  (CK5, CK14, CK17), laminin  and  FAB7  and
the  high  expression  of  proliferation-related  genes  (over-
expression  of  EGFR).  A  P53  mutation  is  observed  in  82%  of
the  cases.
In  clinical  practice,  this  type  corresponds  to  a  determined
histological  phenotype:  grade  III  IDC,  poorly  differentiated,
R−,  HER2−, with  lymphocytic  inﬁltrate,  zones  of  tumoral
necrosis,  ﬁbrotic  central  zone  and  ‘‘pushing’’  outlines  (con-
tinuous  tumoral  ﬂare  front,  without  stroma  reaction).  It
is  a  heterogeneous  group  comprising  85%  of  the  BRCA1,
medullary  and  metaplastic  cancers.In  the  mammogram,  Taneja  observed  fewer  spiculated
masses  (13%)  and  more  masses  with  a  distinct  edge  (47%)
than  in  the  luminal  and  HER2+  sub-groups  [15].  In  the  sono-
gram,  the  halo  is  signiﬁcantly  less  frequent  (19%)  [16].  Other
(
(
p
(E-HER2+. Neo-adjuvant chemotherapy and Trastuzumab. b: forty-
ng ductal carcinoma RE-HER2+. Conservative treatment, adjuvant
s’’, poorly deﬁned of 5 cm. Inﬁltrating ductal carcinoma RE-HER2+.
ata  is  not  available  in  the  literature  concerning  the  imaging
f  the  basal-like  types.
riple-negative type
N  cancers  account  for  7  to  16%  of  all  cancers  and  70%  of  the
umours  occurring  in  BRCA1  mutated  women  [18,19].  They
re  characterized  by  a complete  absence  of  the  expression
f  the  oestrogen  and  progesterone  receptor  gene  and  HER2
‘‘triple  negativity’’)  associated  with  a  high  expression  of
ytokeratin  genes  of  high  molecular  weight  of  type  5/6  or
4  and  EGFR  (epithelial  growth  factor  receptor).
As  regards  the  phenotype,  in  clinical  practice,  this  type
orresponds  to  grade  II  or  more  often  III  or  little  differenti-
ted,  RE−,  HER2− inﬁltrating  carcinomas.
In  the  mammogram,  the  mass  is  the  most  common  pre-
entation,  round,  oval  or  lobular  in  60  to  75%  of  the  cases,
ith  a  circumscribed  edge  in  24%  to  43%  of  the  cases  attest-
ng  to  its  rapid  growth  [11,20—23].  Ko  et  al.  [11]  found
 signiﬁcant  difference  between  TN  and  control  groups
OR+PR-HER−  and  OR+PR-HER+)  for  the  microcalciﬁcations
less  frequent  since  the  TN  tumour  does  not  go  through  the
recancerous  stage)  and  the  focal  asymmetries  of  density
more  frequent  in  the  TN).  However,  the  frequency  of  the
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icrocalciﬁcations  in  this  sub-type  is  assessed  differently
n  the  literature,  more  frequent  in  the  series  by  Boisserie-
acroix  et  al.  [23].  The  rate  of  normal  mammograms  is
ssessed  differently,  from  0  to  18%  [11,20—23].  The  negativ-
ty  of  the  mammogram  may  be  attributed  to  the  ‘‘masking
ffect’’  of  the  breast  density  that  reduces  the  contrast  and
y  the  rapid  evolution  of  these  tumours  that  are  not  accom-
anied  by  architectural  disorganisation.
In  sonography,  a  predominance  of  the  round-oval-lobular
haped  mass  is  found  in  65.1%  to  70%  [17,23],  with  an  indis-
inct  or  microlobulated  contour.  The  tumour-parenchyma
nterface  is  more  often  abrupt  in  TN  tumours  (71  to  84%)
nd  HER  +  tumours  (91%)  than  in  R+HER−  cancers  (64%)
8,11,23].  Very  distinct  hypoechogenicity  is  more  common:
8%  of  the  cases  in  Ko  et  al.’s  series  [11].  The  echostructure
ay  be  heterogeneous  with  zones  of  necrosis,  in  ﬁve  out
f  25  cases  of  tumours  over  3  cm  in  the  study  by  Kojima  and
n
r
r
igure 12. Triple-negative sub-types. a: forty-eight years. Mammogr
uctal carcinoma grade III, oestrogen receptors/progesterone receptors−
ne years. Sonogram: very hypoechogenic 10 mm mass with a circumsc
arcinoma grade II, oestrogen receptors/progesterone receptors− HER−
ass with a circumscribed edge, abrupt interface, with posterior enha
eceptors/progesterone receptors− HER−.M.  Boisserie-Lacroix  et  al.
sunoda  [20]. Posterior  enhancement  is  observed  in  35.5%  to
9%  of  TN  cancers  and  50%  of  R-HER+  cancers  [11,23]  while
t  is  noted  in  only  29%  of  the  R+HER2−  cancers  in  the  study
y  Ko  et  al.  [11]. This  corroborates  Shin  et  al.’s  ﬁndings:  the
osterior  enhancement  is  associated  with  the  high  grade  and
he  negativity  of  the  receptors  [8].  For  Dogan  et  al.,  six  of
he  38  masses  (15.8%)  had  the  characteristics  of  a solid  mass
f  benign  appearance  [22]  (Fig.  12).
In  the  MRI,  the  predominance  of  the  presentation  of  the
ass  type  is  observed  even  more  than  with  conventional
maging:  77.3%  to  97%  of  the  cases  [22—24]. A  T2  hypersignal
s  noted  in  almost  half  of  the  masses.  Dogan  et  al.  attributed
his  to  seats  of  necrosis  although  there  is  not  a  histologi-
al  correlation  in  this  study  [22].  The  existence  of  a  central
ecrosis  is  considered  to  be  a  factor  of  a  poor  prognosis,
elated  to  a  reduction  in  the  free  interval  without  recur-
ence,  with  early  metastatic  dissemination  and  an  increase
am: round mass at the union of the upper quadrants. Inﬁltrating
 HER−: conservative treatment, adjuvant chemotherapy. b: ﬁfty-
ribed edge, non vascularized, pseudo-cystic, ACR 4. Inﬁltrating zf
. c: forty-two years. Sonogram: 18 mm, oval, very hypoechogenic
ncement, ACR4. Inﬁltrating ductal carcinoma grade III, oestrogen
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CCorrelation  between  imaging  and  molecular  classiﬁcation  of
in  the  mortality  (whatever  the  ganglionary  status)  [25,26].
The  morphological  criteria  for  TN  cancers  in  MRI  are  more
suspect  than  in  conventional  radiology  since  the  masses  have
irregular  forms  in  58.3%  of  the  cases,  and  an  angular  edge
in  75%  of  the  cases  [23]  or  even  spiculated  edge  in  41.2%  of
the  cases  [22]  according  to  the  studies.  Annular  enhance-
ment  is  often  observed,  in  76.5%  of  Dogan  et  al.’s  cases  [22]
and  80%  of  Uemastu  et  al.’s  cases  [5]  although  he  did  not
ﬁnd  any  in  the  control  group  (the  comparison  was  carried
out  with  R+HER−  tumours  that  are  rather  a  good  prognosis).
The  positive  predictive  value  of  malignancy  is  high  with  this
type  of  enhancement.  It  is  also  associated  with  poor  progno-
stic  factors  [25].  In  the  study  by  Dogan  et  al.,  among  the  26
masses  with  annular  enhancement,  eight  also  had  enhanced
internal  septa  [22].  Finally,  as  regards  the  kinetics,  a  type
3  enhancement  curve  indicating  malignancy  (early  intense
with  wash-out)  is  noted  in  91%  to  100%  of  the  cases  [22,24].
Apocrine type
Its  more  recent  individualisation  is  still  incomplete.
Clinical implications as regards treatment
Breast  cancer  has  become  a  heterogeneous  disease  with
clinically  pertinent  sub-groups  that  have  a  prognostic  impact
[14].  In  imaging,  beyond  the  characterisation  of  a  mass
and  its  classiﬁcation  in  BI-RADS  ACR  category,  it  is  impor-
tant,  as  of  the  ﬁrst  mammo-sonogram  to  be  familiar  with
the  predictive  characteristics  of  an  aggressive  tumour  sub-
type  in  order  to  organise  the  care  as  quickly  as  possible  for
the  patient:  microbiopsy,  which  remains  indispensable,  and
appointment  with  the  surgeon/oncologist.  In  particular,  the
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Diagram 1. Simpliﬁed phenotypic classiﬁcation of invasive breast
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N  type  evolves  rapidly  and  the  size  of  the  tumour  is  higher
n  young  women  and  should  not  be  confused  with  a  benign
umour  by  the  radiologist.
With  inﬁltrating  breast  cancer,  the  indication  of  adju-
ant  chemotherapy  is  based  on  the  analysis  of  the  classic
linicopathological  factors  and  decided  on  during  a  meeting
nvolving  multidisciplinary  agreement  based  on  the  rec-
mmendations  of  the  consensus  conferences  (St-Gallen,
t-Paul-de-Vence.  . .). At  the  same  time,  during  the  last
ecade,  expression  proﬁles  have  helped  deﬁne  tumours  with
 different  prognosis,  opening  the  way  to  therapeutic  strate-
ies  adapted  to  the  tumour  proﬁle,  and  even  to  a  prediction
f  the  response  or  non  response  to  chemotherapy.
For  example,  in  patients  with  a  ‘‘good  prognosis’’,  with-
ut  ganglion  invasion,  with  R+  tumour  and  grade  II  (luminal
 and  B  type),  the  high  genome  grade  (genes  associated  with
he  proliferation  and  regulation  of  the  cell  cycle,  high  Ki67)
nd  the  low  genome  grade  now  enable  the  indication  for
hemotherapy  to  be  validated  or  rejected.
Genome  analysis  tests  have  been  commercialised.  The
rice  is  very  high  and  they  are  not  reimbursed  or  used  in
rance  and  are  waiting  for  the  conclusions  of  the  thera-
eutic  trials  (ex.  MINDACT,  based  on  a  ‘‘signature  with  70
enes’’,  Mammaprint)  carried  out  to  validate  the  reliability
f  genome  analysis  in  everyday  practice.
onclusione  will  note  the  signiﬁcantly  more  frequent  aspects,  based
n  current  knowledge  (Diagram  1):
stellar  mammogram-irregular  mass  with  echogenic  halo  in
luminal  A  sub-type;
e breast can cers , signiﬁcan tly more 
phy/MRI and  syste mic treatments  
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HER2 + 
Regar dless  of Ki67   
HER2 -
 
HER2 +Type Triple negave type
Irregular  mass  
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Ind isnct edge 
Post en hancement 
Non-mass  
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 cancers, signiﬁcantly more frequent aspects in mammogra-
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architectural  distortion  in  luminal  B  sub-type;
irregular  mass  with  an  indistinct  edge,  with  an  abrupt
interface  in  the  sonogram,  or  of  sonogram  non-mass  in
the  HER2  sub-type;
lobulated  mass  with  an  indistinct  edge  or  microlobulated,
very  hypoechogenic,  with  an  abrupt  interface,  pseudo-
benign,  with  annular  enhancement  in  the  MRI  in  the  triple-
negative  sub-type.
It is  necessary  to  back  up  these  correlations  between  the
maging  and  molecular  classiﬁcation  by  more  statistically
owerful  studies.
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